M
Monopar Therapeutics D
D
MNPR
53.210
USD
0.34
(0.63%)
Market Open
Volume
2,287
EPS
-3
Div Yield
-
P/E
-29
Market Cap
356,088,769
Title: Monopar Therapeutics Inc
Sector: Healthcare
Industry: Biotechnology
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company developing a treatment for Wilson disease and novel radiopharmaceuticals for oncology. Its Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. The group radiopharmaceutical programs consist of Phase 1-stage MNPR-101-Zr for imaging cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac for the treatment of cancers that express urokinase plasminogen activator receptor (uPAR). It build drug development pipeline through both in-house efforts and licensing of late preclinical- and clinical-stage therapeutics. The Company operates as a single reportable segment, focusing on the development of clinical and preclinical product candidates.